溃疡性结肠炎治疗药物的定位
本文综述溃疡性结肠炎(UC)现有治疗药物类别及已提出的治疗算法,指出这些算法多基于专家意见而非高质量证据,主要因缺乏头对头试验,尤其单克隆抗体与小分子药物,故各疗法的优化定位仍不明确。
要点
- UC可用药物包括水杨酸类、糖皮质激素、硫嘌呤、钙调磷酸酶抑制剂、抗TNF、抗黏附分子、JAK抑制剂及乌司奴单抗。
- 现有治疗算法多基于专家意见,缺乏高质量证据,尤其单抗与小分子药物间缺头对头试验。
- 各疗法在治疗算法中的优化定位尚不明确,需更多证据。
核心结论
- UC治疗算法多基于专家意见而非高质量证据,各疗法的优化定位仍不明确。
研究设计与样本
- 本文为文献综述,检索并汇总现有证据,以提供UC治疗药物定位的最新概览。
主要发现
- UC可用药物包括水杨酸类、糖皮质激素、硫嘌呤、钙调磷酸酶抑制剂、抗TNF药物、抗黏附分子、JAK通路小分子药物及乌司奴单抗。
- 其他药物正在开发中,可能不久的将来可用于UC患者。
- 已提出多种UC治疗算法,但主要基于专家意见,因缺乏头对头试验,尤其单抗和小分子疗法。
临床怎么用
- 临床选择UC治疗药物时需认识现有算法证据级别有限,结合专家意见与可用证据个体化决策。
局限性
- 缺乏头对头试验,尤其单克隆抗体和小分子药物之间,导致治疗算法证据质量不高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ulcerative colitis (UC) is a chronic, idiopathic inflammatory bowel disease (IBD) that affects the large intestine. Several therapeutic drug classes are available for the treatment of UC: salicylates, corticosteroids, thiopurines, calcineurin inhibitors, anti-tumor necrosis factor (TNF) agents, anti-adhesion molecules, and, more recently, small molecules directed against the Janus kinase (JAK) pathways, and ustekinumab (anti IL12/23). Other drugs are currently in development, and they will be probably available for UC patients in the near future. Several therapeutic algorithms have been proposed for the treatment of UC patients, yet these are predominantly based on expert opinions rather than high-quality evidence, mainly due to the lack of head-to-head trials, especially for monoclonal antibody and small molecule therapies. The optimal position of therapies in these algorithms remains unclear. Therefore, we conducted this review of the literature to provide an up-to-date overview of the available evidence on this topic.
引用
- Danese S, Fiorino G, Peyrin-Biroulet L, et al. Positioning Therapies in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020. PMID: 31982609. doi:10.1016/j.cgh.2020.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。